MarketCap
Facebook
X
TelegramQuarterly report 2024-Q4
added 01-10-2025
Accolade EBITDA 2011-2026 | ACCD
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Accolade
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -38.6 M | -39.7 M | -44.6 M | -51.5 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -38.6 M | -51.5 M | -43.6 M |
Quarterly EBITDA Accolade
| 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -112 M | -14.5 M | -18.7 M | - | -20.3 M | -24.4 M | -28 M | - | -28.8 M | -34.3 M | -334 M | - | 37.8 M | -64.9 M | -103 M | -39.3 M | -14.4 M | -10.4 M | -8.92 M | -10.7 M | -15.4 M | -12 M | -13.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 37.8 M | -334 M | -43.5 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Health information services industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Change Healthcare
CHNG
|
691 M | - | - | $ 9.03 B |  USA |
 |
Phreesia
PHR
|
-107 M | $ 11.2 | -0.75 % | $ 611 M | USA |
 |
Cerner Corporation
CERN
|
1.43 B | - | - | $ 27.9 B | USA |
 |
American Well Corporation
AMWL
|
-71.3 M | $ 5.76 | - | $ 92.4 M | USA |
 |
Computer Programs and Systems
CPSI
|
-40.7 M | - | 4.4 % | $ 133 M | USA |
 |
Covetrus
CVET
|
148 M | - | - | $ 2.94 B | USA |
 |
iCAD
ICAD
|
-6.03 M | - | - | $ 102 M | USA |
 |
Castlight Health, Inc.
CSLT
|
-5.95 M | - | -7.28 % | $ 227 M | USA |
 |
Schrödinger
SDGR
|
-161 M | $ 11.65 | 0.69 % | $ 856 M | USA |
 |
HMS Holdings Corp.
HMSY
|
140 M | - | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
187 M | - | - | $ 6.37 B | USA |
 |
NextGen Healthcare
NXGN
|
20.8 M | - | - | $ 1.6 B | USA |
 |
1Life Healthcare
ONEM
|
-197 M | - | - | $ 3.37 B | USA |
 |
Premier
PINC
|
119 M | - | - | $ 2.33 B | USA |
 |
Teladoc Health
TDOC
|
87.8 M | $ 5.58 | 3.05 % | $ 983 M | USA |
 |
Omnicell
OMCL
|
82.6 M | $ 34.8 | 0.97 % | $ 1.6 B | USA |
 |
OptimizeRx Corporation
OPRX
|
-24 M | $ 7.1 | 4.72 % | $ 122 M | USA |
 |
Evolent Health
EVH
|
70.8 M | $ 2.32 | 2.88 % | $ 217 M | USA |
 |
MTBC
MTBC
|
26.3 M | - | -0.58 % | $ 51.7 M | USA |
 |
GoodRx Holdings
GDRX
|
135 M | $ 2.09 | 2.21 % | $ 806 M | USA |
 |
Signify Health
SGFY
|
63.3 M | - | -0.02 % | $ 7.21 B | USA |
 |
R1 RCM
RCM
|
223 M | - | - | $ 3.81 B | USA |
 |
Akerna Corp.
KERN
|
-6.57 M | - | - | $ 161 M | USA |
 |
SCWorx Corp.
WORX
|
-1.26 M | $ 0.13 | 5.52 % | $ 190 K | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
253 M | - | -10.39 % | $ 886 M | USA |
 |
Zhongchao
ZCMD
|
-110 K | $ 1.82 | 0.28 % | $ 9.47 M |  China |
 |
Health Catalyst
HCAT
|
-110 M | $ 1.11 | 1.32 % | $ 77.6 M | USA |
 |
HealthEquity
HQY
|
477 M | $ 82.29 | 0.23 % | $ 7.09 B | USA |
 |
HealthStream
HSTM
|
62.5 M | $ 21.24 | 1.29 % | $ 645 M | USA |
 |
NantHealth
NH
|
-35.3 M | - | -46.64 % | $ 10.4 M | USA |
 |
10x Genomics
TXG
|
-230 M | $ 21.03 | 6.16 % | $ 2.46 B | USA |
 |
Streamline Health Solutions
STRM
|
-3.18 M | - | - | $ 21.4 M | USA |
 |
Tabula Rasa HealthCare
TRHC
|
-45.6 M | - | - | $ 255 M | USA |
 |
Progyny
PGNY
|
19 M | $ 17.65 | -2.22 % | $ 1.51 B | USA |
 |
So-Young International
SY
|
-579 M | $ 3.12 | 7.04 % | $ 248 M | China |
 |
Veeva Systems
VEEV
|
930 M | $ 179.16 | 0.03 % | $ 29.3 B | USA |